SAI PARENTERALS LIMITED
₹ 372 - ₹ 392
24-Mar-2026 - 27-Mar-2026
₹ 14896.00

/ 38 Shares

SAI PARENTERALS LIMITED

24-Mar-2026 - 27-Mar-2026

₹ 372 - ₹ 392

Price Band

₹ 14896.00

Minimum Investment

38

Bid Lot

10,428,288

Shares

  • Face Value - ₹ 5/- Per Share

  • Listing at NSE BSE

  • 96,050 Application Required in Retail for 1 Time.

  • Registrar : Bigshare Services Pvt. Ltd

IPO Details

Fresh Issue of Equity Shares aggregating to Rs. 285 Cr and Offer for sale of 3,157,880 Equity Shares

Category % Shares/Amount
QIB 50% 5,214,143 Shares RS.204.39 CR
HNI 1 5% 521,415 Shares RS.20.44 CR @ 980 FORM 1X
HNI 2 10% 1,042,829 Shares RS.40.88 CR @ 1960 FORM 1X
Retail 35% 3,649,901 Shares RS.143.08 CR @ 96050 FORM 1X

BRLMs: Arihant Capital Markets Ltd

Application Require for 1 Time

Retail (Upto 2 Lakh) HNI (2 Lakh to 10 Lakh) HNI (Above 10 Lakh)
96050 FORM 1X 980 FORM 1X 1960 FORM 1X

IPO Lot Size

Category Lots Shares Amount
Retail (Upto 2 Lakh) 1 38 ₹ 14,896
Retail (Upto 2 Lakh) 13 494 ₹ 193,648
S-HNI (2 Lakh to 10 Lakh) 14 532 ₹ 208,544
S-HNI (2 Lakh to 10 Lakh) 67 2546 ₹ 998,032
B-HNI (Above 10 Lakh) 68 2584 ₹ 1,012,928

IPO Timeline

  • Open Date

    24-Mar-2026

  • Close Date

    27-Mar-2026

  • Basis of Allotment Date

    30-Mar-2026

  • Initiation of Refunds

    01-Apr-2026

  • Credit Shares to Demat A/c

    01-Apr-2026

  • IPO Listing Date

    02-Apr-2026

About Company

  • q The Company was originally incorporated as Sai Parenteral’s Private Limited on January 12, 2001, in Hyderabad. Subsequently, on conversion into a public limited company the name was changed to Sai Parenteral’s Limited on January 17, 2022.
  • q The Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. The company is in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets.
  • q The Company’s portfolio includes formulation products across various therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology, with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments.
  • q The company manufactures and sells Branded Generic Formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market.
  • q The company exports its products to the Regulated and Semi-Regulated Markets of Australia, New Zealand, Southeast Asia, Middle East and Africa through distributors.
  • q The company has 5 Manufacturing Facilities, of which 4 are in Hyderabad, Telangana and 1 manufacturing facility in Ongole, Andhra Pradesh, which is operated by its Subsidiary, Revat Laboratories.
  • q The Manufacturing Facilities are spread across an aggregate area of 1,14,540 sq. ft. and have a combined installed capacity of 1,160 million units per annum on a single shift basis.
  • q The company has developed a comprehensive, diversified portfolio of 302 pharmaceutical products, spanning both high-value and high-volume categories.
  • q As of date, the company has 55 dossiers developed in-house, out of which 45 dossiers are approved by the FDA, Philippines and another 14 dossiers transferred by third-party CDMO customers under tech transfer agreements. Further, it plans to file 60 new product dossiers by FY 2028 across key Regulated and Semi-Regulated Markets. 
  • q As of December 31, 2025, the company supplied Branded Generic Formulation products to 10 countries through a network of 7 distributors.
Read More

Strengths

Competitive Strength 

Business Strategies 

  • Expansion into global injectable formulations market
  • Capitalise on the CDMO opportunity by leveraging the manufacturing capabilities with enhanced R&D competencies
  • Strengthening the presence in Regulated Markets through Noumed’s upcoming manufacturing facility in Adelaide, Australia
  • Focus on new product development to drive future growth
  • Grow the Branded Generic Formulations business by leveraging opportunities in the international markets
  • Expand capabilities through strategic acquisitions

Company Promoters

Company Financials

Period Ended 30 Sep 2025 31 Mar 2025 31 Mar 2024 31 Mar 2023
Assets 376.24 272.39 268.10 133.96
Total Income 89.43 163.74 155.18 97.03
Profit After Tax 7.76 14.43 8.42 4.38
EBITDA 16.24 39.44 31.70 17.64
NET Worth 209.37 95.78 76.40 31.49
Reserves and Surplus 188.84 80.36 61.30 24.34
Total Borrowing 76.07 93.95 118.79 68.55
Amount in ? Crore

Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

# Issue Objects Est Amt (? Cr.)
1 Capacity expansion and upgradation of manufacturing facilities 110.80
2 Establishment of a new R&D Centre; 18.02
3 Repayment / prepayment of certain outstanding borrowings 14.30
4 Working capital requirements 33.00
5 Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and 35.64
6 General corporate purposes  
  Total 211.76

How to Apply

Apply for IPO in few simple steps.

  • Step 01 :

    Once you create your account, Login to InvestoYard.

  • Step 02 :

    Under IPO Section, you will be able to see a list of Ongoing IPOs, where you can click on apply button.

  • Step 03 :

    Add quantity of shares to apply – Maximum 3 bids are allowed (For retail category – max amount Rs.2,00,000/-).

  • Step 04 :

    Enter your UPI ID and you will receive mandate on your UPI App.

  • Step 05 :

    Once you accept the mandate, Application is submitted successful.

  • Applying for an IPO is easier than ever with InvestoYard, in just a few clicks your application is processed. You can bid for any IPO through InvestoYard, the bidding process is simple and hassle free. Every company has a lot size decided & you can buy in multiples of the decided lot.
  • If lot size is 15, then you have to bid for multiples of 15 share like 30,45,60 and so on.
  • The maximum subscription amount for retail investors is 2 lakh.
  • Any bid can be at a desired price or cut off price given by the company.

  • Enter the number of shares you wish to buy, as per the lot size.
  • You can apply at the cut off price set by the company or bid for a desired amount within the price band.
  • Maximum three bids will be accepted.
  • You then need to enter the UPI ID on InvestoYard’s IPO application form.

  • You will immediately get a fund blocked request on your UPI for the submitted IPO application.
  • The funds will be blocked in your bank account until allotment when it is debited.
  • The limit for IPO application is Rs 2 lakh per transaction on UPI.
  • On allotment of the shares, the money will be automatically debited.
  • If the share aren’t allotted the blocked funds will reflect back into your account.

Frequently Asked Questions

Apply Now